Quick10K

⚲

Cyanotech

Filings

10-Q	2019-12-31	Filed 2020-02-11
10-Q	2019-09-30	Filed 2019-11-12
10-Q	2019-06-30	Filed 2019-08-13
10-K	2019-03-31	Filed 2019-07-01
10-Q	2018-12-31	Filed 2019-02-13
10-Q	2018-09-30	Filed 2018-11-13
10-Q	2018-06-30	Filed 2018-08-13
10-K	2018-03-31	Filed 2018-06-15
10-Q	2017-12-31	Filed 2018-02-06
10-Q	2017-09-30	Filed 2017-11-06
10-Q	2017-06-30	Filed 2017-08-10
10-K	2017-03-31	Filed 2017-06-22
10-Q	2016-12-31	Filed 2017-02-07
10-Q	2016-09-30	Filed 2016-11-10
10-Q	2016-06-30	Filed 2016-08-15
10-K	2016-03-31	Filed 2016-06-23
10-Q	2015-12-31	Filed 2016-02-11
10-Q	2015-09-30	Filed 2015-11-12
10-Q	2015-06-30	Filed 2015-08-07
10-K	2015-03-31	Filed 2015-07-15
10-Q	2014-12-31	Filed 2015-02-12
10-Q	2014-09-30	Filed 2014-11-12
10-Q	2014-06-30	Filed 2014-08-14
10-K	2014-03-31	Filed 2014-06-27
10-Q	2013-12-31	Filed 2014-02-06
10-Q	2013-09-30	Filed 2013-11-07
10-Q	2013-06-30	Filed 2013-08-12
10-K	2013-03-31	Filed 2013-06-24
10-Q	2012-12-31	Filed 2013-02-07
10-Q	2012-09-30	Filed 2012-11-09
10-Q	2012-06-30	Filed 2012-08-10
10-K	2012-03-31	Filed 2012-06-21
10-Q	2011-12-31	Filed 2012-02-09
10-Q	2011-09-30	Filed 2011-11-14
10-Q	2011-06-30	Filed 2011-08-11
10-K	2011-03-31	Filed 2011-06-23
10-Q	2010-12-31	Filed 2011-02-11
10-Q	2010-09-30	Filed 2010-11-10
10-Q	2010-06-30	Filed 2010-08-12
10-K	2010-03-31	Filed 2010-06-24
10-Q	2009-12-31	Filed 2010-02-11

Reports

8-K	2020-05-05	Enter Agreement, Off-BS Arrangement, Exhibits
8-K	2019-08-22	Shareholder Vote
8-K	2019-06-03	Enter Agreement, Leave Agreement, Officers
8-K	2019-04-26	Officers
8-K	2019-04-12	Enter Agreement, Off-BS Arrangement
8-K	2019-01-03	Officers, Other Events
8-K	2018-11-30	Enter Agreement, Exhibits
8-K	2018-11-06	Officers
8-K	2018-08-31	Other Events, Exhibits
8-K	2018-08-27	Shareholder Vote
8-K	2018-04-13	Other Events
8-K	2018-01-24	Enter Agreement, Officers, Other Events

Cyanotech Financials

CYAN Metrics, Comps, Filings

Quarterly | Annual

Business

Unless otherwise indicated, all references in this report to the "Company", "we", "us", "our", and "Cyanotech" refer to Cyanotech Corporation and its wholly owned subsidiary, Nutrex Hawaii, Inc. ("Nutrex Hawaii" or "Nutrex"), a Hawaii corporation.

We are a world leader in the production of high value natural products derived from microalgae. Incorporated in 1983, we are guided by the principle of providing beneficial, quality microalgal products for health and human nutrition in a sustainable, reliable and environmentally sensitive operation. We are GMP (Good Manufacturing Practices) certified by the Natural Products Association™, reinforcing our commitment to quality in our products, quality in our relationships (with our customers, suppliers, employees and the communities we live in), and quality of the environment in which we work. Our products include:

- Hawaiian BioAstin® natural astaxanthin - a powerful dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health. It has expanding applications as a human nutraceutical and functional food ingredient; and - Hawaiian Spirulina Pacifica® - a nutrient-rich dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids

Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Equity

Income Statement ($BB Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($BB Quarterly)

Ops, Inv, Fin


Comps ($MM TTM)	Market Cap	Gross Margin	EV/EBITDA	Ret on Assets	Assets	Liabilities	Revenue	G Profit	Net Income	EBITDA	EV
Nexeo Solutions (NXEO)	757	11%	9.1	1%	2,179	1,360	4,040	452	19	169	1,533
Innophos Holdings (IPHS)	681	18%	20.0	2%	876	538	759	135	21	49	991
Hawkins (HWKN)	453	18%	9.4	7%	393	164	549	98	27	55	524
OMNOVA Solutions (OMN)	254	23%	10.7	1%	584	524	760	178	6	50	540
Foamix Pharmaceuticals (FOMX)	188	74%	-2.8	-70%	82	28	1	1	-57	-57	160
MediWound (MDWD)	118			0%	35		0	0	0	0	118
Natural Alternatives International (NAII)	60	16%	4.0	4%	115	38	131	21	4	8	31
Mannatech (MTEX)	40	80%	1.4	2%	67	42	118	95	1	6	8
China Jo-Jo Drugstores (CJJD)	40	24%	-45.8	-3%	87	66	111	26	-3	-0	22
Ocean Bio Chem (OBCI)	31	38%	8.3	7%	39	9	33	12	3	4	31
Cyanotech (CYAN)	19	41%	31.4	-3%	32	17	32	13	-1	1	25
CTI Industries (CTIB)	8	16%	-2.5	-16%	33	31	33	5	-5	-4	9
Fuwei Films (FFHL)	7	14%	4.5	-2%	455	258	304	42	-9	-9	-40
Chromadex (CDXC)	0	55%	0.4	-54%	43	16	33	18	-23	-22	-9
Aurora Cannabis (ACB)
Cronos Group (CRON)
HEXO (HEXO)
Aphria (APHA)
Canopy Growth Corporation (CGC)
Happiness Biotech (HAPP)				0%	66	5	0	0	0	0	-15


Balance Sheet ($MM)	2011-06-30	2011-09-30	2011-12-31	2012-03-31	2012-06-30	2012-09-30	2012-12-31	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31	2019-06-30	2019-09-30
Cash	3	4	4	5	5	4	4	4	3	3	3	4	3	3	3	2	2	2	2	1	2	2	2	1	1	2	2	1	1	1	2	1	1	1
Accounts Receivable	3	3	3	2	3	4	4	4	4	4	5	3	3	4	4	3	4	4	3	3	2	3	2	2	3	2	3	3	3	2	2	2	2	2
Inventory	3	3	4	4	3	3	3	4	4	4	5	5	5	5	7	6	6	6	7	8	8	7	8	8	8	9	10	9	9	10	10	11	12	11
PP&E			5	6	6	7	8	9	10	11	11	12	12	13	20	15	21	22	29	31	32	32	32	32	32	32	32	33	33	33	33	34	34	34
Assets	14	16	17	19	19	22	23	29	29	29	30	30	30	32	32	31	32	35	35	31	31	31	30	29	29	30	31	30	30	29	30	30	34	32
Accounts Payable	1	1	1	2	1	2	2	2	2	2	2	3	3	4	4	3	3	4	4	4	4	4	4	4	3	3	4	4	4	4	4	5	4	3
Long-Term Debt	1	1	1	1	0	2	2	5	5	6	6	5	5	5	5	5	5	8	8	7	8	7	7	7	7	7	7	7	7	6	6	6	7	7
Liabilities	3	3	3	4	3	6	5	8	9	9	9	9	10	11	10	9	10	13	13	13	14	14	13	13	12	12	12	12	13	13	13	15	18	17
Stockholders' Equity		13	14	15	16	17	17	20	20	21	21	21	21	21	22	21	22	22	22	18	17	17	17	17	17	18	19	18	17	16	16	15	15	15


Income Statement ($MM)	2011-06-30	2011-09-30	2011-12-31	2012-03-31	2012-06-30	2012-09-30	2012-12-31	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31	2019-06-30	2019-09-30
Revenue	6	6	7	6	7	7	7	7	7	7	7	7	7	9	9	9	8	9	8	8	7	10	8	7	9	8	9	8	7	7	10	6	8	8
Cost of Revenue	4	3	4	4	4	4	4	4	4	4	4	5	4	4	4	6	5	5	4	5	5	6	5	5	5	4	5	6	5	5	6	4	4	5
Gross Profit	2	3	3	2	3	3	3	3	3	3	3	3	3	4	4	3	3	3	3	3	3	4	3	3	4	4	4	2	2	2	4	2	4	3
R&D	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SG&A	2	2	2	2	2	2	2	2	3	2	3	3	4	4	3	3	3	3	3	3	3	4	3	3	3	3	3	3	3	3	3	3	3	2
Tax	0	0	0	0	0	0	0	0	0	0	0	0	-1	0	0	0	0	-0	0	3	0	0	0	0	0	0	0	0	0	0	0	-0	-0	-0
Net Income	0																			-4	-1	0	-0	-0	1	1	1	-1	-1	-1	0	-1	-0	0


Cash Flow ($MM)	2011-06-30	2011-09-30	2011-12-31	2012-03-31	2012-06-30	2012-09-30	2012-12-31	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31	2019-06-30	2019-09-30
Cash Operating	1		1	2	0	0	0	1	-0	0	-0	2	-0	1	0	1	-0	0	1	-0	0	1	-0	0	0	1		0	-1	-0		-1
Cash Investing	-0		-1	-1	-1	-3	-0	-4	-1	-0	-1	-0	-1	-1	-1	-1	-1	-2	-1	-0	-0	-0	-0	-0	-0	-0		-0	-0	-0		-0
Cash Financing	-0		0	-0	-0	2	-0	3	-0	0	-0	-0	-0	-0	0	0	0	2	-0	-0	0	-0	-0	-0	-0	-0		-0	1	0		0